Recommended as a possible helpful treatment by Dr Vallings in NZ. Her idea of it as something a pwME might want to try is based on the discovery of low B12 in the cerebrospinal fluid.
The following are some excerpts from something I drafted in response to Dr Vallings promoting B12 injections in the treatment of ME/CFS in a recent editorial in a journal for doctors:
Vitamin B12 injections is one treatment that illustrates a number of the issues. Dr Vallings suggests in the editorial that B12 injections have been shown to be useful, noting that ‘cerebrospinal fluid levels maybe depleted’. The reference given for this is a 2015
Finnish study that did not in fact measure levels of B12 in cerebrospinal fluid (CSF) or in blood. The retrospective study consisted of 38 patients who had been having at least weekly injections of B12 and folic acid for varying lengths of time, from 6 months up to 20 years. All of the included patients had previously ‘reported an evident and favourable response to B12 injections in an open clinical environment’. None of the possibly many people who did not find B12 injections useful were included in the study.
There are many more issues, summarised here as:
· No patient had been treated exactly the same over the years, with dosages and types of B12 varying.
· B12 was combined with folic acid, making separation of the effect of B12 impossible.
· Patients self-reported global improvements on a scale of 1 to 3, making the study open to a range of biases, particularly as ME/CFS is a fluctuating condition.
· An evaluation of current illness level was made and it was this that was used to determine whether a person was a ‘good’ or ‘mild’ responder (15 and 23 people respectively). But current illness level says little about improvement. Furthermore, the evaluation gave points for both fatigue and fibromyalgia symptoms, so those with both fatigue and fibromyalgia unsurprisingly scored worse.
· It was confounded by high rates of analgesic and thyroid medication use.
That 2015 study quotes a
1997 study as finding that ‘levels of CSF B12 were generally low’.
The 1997 study had its own set of problems:
· Small size - 24 patients ranging in age from 22 to 64. However, CSF B12 data is only reported for 12 patients, with no explanation for the drop outs.
· Poor selection criteria - the criteria did not require that the patients had the core ME/CFS symptom of post-exertional malaise but did require fibromyalgia symptoms
· There was no control group to ensure that approaches to CSF collection, storage and processing were consistent with comparison data
· The authors noted that the ‘method we used to analyse the concentration of CSF-B12 needs to be further validated’.
· There is no information as to how the normal range of CSF B12 was determined including whether it was appropriate for the patients’ age range.
·
Only one of the 12 patients was found to have a level of CSF B12 that was deemed low (with most of the others being deemed borderline, and two in the normal range).
Therefore, the recommendation for B12 injections is based on a single 1997 study with 12 participants (who may or may not have had ME/CFS), no controls and a quantification method that the authors acknowledged ‘needs to be further validated’. Even then, the study did not find overwhelming evidence for low levels of B12 in cerebrospinal fluid.
And the 2015 study of 38 hand-picked self-reported responders to B12 injections described the majority as being only ‘mild responders’.
Clinicians may say ‘I don’t need trial evidence’, I see some of my patients responding, they tell me it helps’. But the placebo treatment in the blinded rituximab trial produced a self-reported improvement in 40% of the participants in that cohort. ME/CFS is a fluctuating disease and patients typically reduce activity over time, by for example, giving up work, in order to reduce symptoms. In these circumstances, especially when both patients and doctors want to believe that an intervention is helping, self-reported improvement is not a reliable measure of efficacy.
Some may say, ‘well, what does it matter? If the patient is happy that they are doing something that helps, isn’t that giving them hope, isn’t that good enough?’. Similar arguments may be made for other treatments Dr Vallings suggests such as acupuncture, ‘good breathing technique’ and self-hypnosis.
But it does matter. A person with ME/CFS is having to make hard decisions about how to ration their energy. They may only have one shower a week instead of two, in order to have enough energy to get to the clinic for the treatment. They may be sick from the exertion of the trip for several days afterwards and not be able to interact with their child during that time. A person with ME/CFS is probably not able to work and so is having to make difficult decisions about how to ration funds. The cost of the B12 injection, or the acupuncture, may mean that they cannot afford to have fresh food delivered or donate to research efforts. If there is no reasonable chance of a benefit, there is harm.
Furthermore, listing unevidenced and probably ineffective treatments obscures the fact that there is really very little that significantly helps the actual disease other than reduced activity levels. It can suggest to skeptics that all people with ME/CFS need is a good placebo and some encouraging words.
Dr Vallings is absolutely right that so much is lost by people with ME/CFS; it is a devastating disease. Care needs to be taken to ensure that clinical practice is based on sound evidence and acknowledges remaining uncertainties.